Preceptor Update: Initiating MOUD in the Age of Fentanyl


Now that a waiver is no longer required to prescribe buprenorphine, all providers who possess a DEA license with the ability to prescribe schedule III controlled substances need to be prepared to initiate buprenorphine for patients who have opioid use disorder.  This training serves as an update for providers who took waiver training prior to 2022 or as an introduction for those who are new to the practice of prescribing buprenorphine, with consideration to changes in Philadelphia area drug supply over the last 3 years.

This program also includes a session describing the use of injectable buprenorphine with an emphasis on patient selection, site preparation, troubleshooting, and administration.  Nurses are encouraged to attend.

Providers who complete this session are eligible to schedule a CME accredited observation session with an experienced faculty preceptor at our partner outpatient health centers. This optional opportunity is scheduled
"individually on a first come, first serve basis and must be planned at least 4 weeks in advance for CME purposes.

On-site observation is limited to MD/DO/NP/PAs who practice within Philadelphia County.

Space is limited.

Where: Online

Accreditation: CME, Nursing

Learning Objectives: After attending this program, participants will be able to:

  1. Describe current initiation methods for medications for opioid use disorder and comfort medications for patients who use fentanyl and xylazine.
  2. Describe practices related to prescribing long acting injectable buprenorphine.


  • Initiating medications for opioid use disorder

Joseph D'Orazio, MD, FAAEM, FACMT, Associate Professor of Clinical Emergency Medicine, Director, Division of Medical Toxicology & Addiction Medicine

Joseph D'Orazio, MD, FAAEM, FACMT is an emergency physician, medical toxicologist, and addiction medicine specialist at Lewis Katz School of Medicine at Temple University. He cares for Temple patients in a variety of settings, including the emergency department, an inpatient consultative service for addiction medicine and toxicology, the TRUST Clinic (an office-based opioid treatment program), and Begin the Turn (Temple's low-barrier access street-side medicine program). He is also a consultant for the Poison Control Center at Children’s Hospital of Philadelphia. 

  • Starting Long Acting Injectable Buprenorphine: Site Preparation, Patient Selection, and Troubleshooting 

Kara Cohen, CRNP, Associate Director of Project HOME Street Medicine

Project HOME Street Medicine is a satellite health clinic of Project HOME Health Services (PHHS). In her role, Kara provides streetside primary care services, including connecting people to MOUD treatment and managing wounds related to injection drug use. In her previous role as the Assistant Site Director for PHHS' Pathways clinic, she facilitated the roll out of the utilization of Long Acting Injectable Buprenorphine (LAIB), with a focus on incorporating LAIB as part of the harm reduction model. Ms. Cohen focuses on meeting patients where they are, and building trust with patients who may have had negative experiences with health care providers in the past.


March 24, 2023
9:00 am — 12:00 pm
Training Type Preceptor Trainings